GlassScriptPhysician profile
James L Hiller
NPI 1235187659
$3,620.88
in general payments reported to CMS, 2019-2025
30 companies · $423 in 2025
The $423 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $281 · 2021: $413 · 2022: $923 · 2023: $739 · 2024: $575 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.38 |
| Education | $229.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $773.35 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $605.28 | 2020-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $546.08 | 2019-2024 | |
| Myovant Sciences INC. | $433.52 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $304.88 | 2019-2025 | |
| Hologic Sales and Service, LLC | $129.67 | 2019-2024 | Thinprep 2000 Processor, Aptima |
| Evofem Biosciences, INC. | $123.73 | 2020-2022 | |
| Caldera Medical, INC | $69.12 | 2022 | |
| Lilly USA, LLC | $63.23 | 2025 | Zepbound, Mounjaro |
| Avion Pharmaceuticals | $51.79 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $50.43 | 2019-2020 | |
| Biogen, INC. | $47.07 | 2025 | Zurzuvae |
| Pfizer INC. | $42.42 | 2019-2022 | |
| Baxter Healthcare | $41.34 | 2024-2025 | Perclot |
| Therapeuticsmd, INC. | $38.25 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $36.99 | 2020-2021 | |
| Agile Therapeutics, INC. | $30.12 | 2021-2022 | |
| Abbott Laboratories | $29.77 | 2023-2025 | Freestyle Libre 3 |
| Sage Therapeutics, LLC | $24.57 | 2024 | |
| Scynexis, INC. | $21.87 | 2022 | |
| Optumhealth Care Solutions, LLC | $20.58 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Coloplast Corp | $19.16 | 2022 | |
| Neuronetics, INC. | $17.23 | 2022 | |
| Merck Sharp & Dohme LLC | $17.09 | 2021 | |
| Axonics, INC. | $15.39 | 2021 | |
| Millicent US INC | $15.17 | 2024 | Intrarosa, Femring |
| Shield Therapeutics INC | $14.73 | 2023 | Accrufer |
| Horizon Therapeutics Plc | $13.80 | 2019 | |
| Minerva Surgical, INC | $12.25 | 2021 | |
| Lupin INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.